Publications

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.

Morgado-Cáceres P. et al, (2026), Oncoimmunology, 15

Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I

Murali TM. et al, (2026)

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Beernaert B. et al, (2026), Science advances, 12

Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B.

Kalafateli M. et al, (2026), Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 24, 701 - 712.e8

Tumor-targeted 4-1BB costimulation enhances immune activation and clinical activity of a CEA-directed T-cell engager in microsatellite-stable colorectal cancer

Boehnke A. et al, (2026)

Supplementary Figure 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Supplementary Figure 5 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Supplementary Figure 7 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Supplementary Figure 2 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Figure S8 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Supplementary Methods 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Supplementary Figure 6 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Figure S9 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Supplementary Figure 4 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Data from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Melero I. et al, (2026)

Cookies on this website

Search results (3169)